ASX
LCT 0.02   Last updated EOD 21st October 2019
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

Home

Cell therapy for neurodegenerative diseases

LCT is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which  include naturally occuring cells to restore function.

 

Our lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.

 

The Phase I/IIa clinical trial of NTCELL for the treatment of Parkinson’s disease, in New Zealand, met the primary endpoint of safety and in the three-year follow-up showed persistent long-term improvement in some patients.


Results from this trial were used to design a larger Phase IIb trial to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. This trial commenced in March 2016. 

 

At 24 months post implant the 4 people with Parkinson’s disease who received 80 capsules continue to show a benefit as measured by the change in the Unified Parkinson’s Disease Rating Scale (UPDRS Part III in the off state). This was greater than the 2 placebo group in that section of the Trial, but not when compared to all the 6 placebo patients (4 from the other groups) in whom responses were quite varied. 


In addition to Parkinson’s disease, NTCELL has the potential to be used in a number of other central nervous system indications, including Huntington’s, Alzheimer’s and motor neurone diseases including amyotrophic lateral sclerosis (ALS).

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges and is incorporated in Australia, with operations based in New Zealand.

— 15 October 2019

LCT extends cash runway with receipt from Vertex

LCT has received Net AUD 1,100,158 from the acquisition of Semma Therapeutics, a private company in which LCT held shares, by Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Read More Read Less

— 4 October 2019

Notice of AGM and proxy form

NOTICE OF ANNUAL GENERAL MEETING DATE OF MEETING Thursday 7 November 2019 TIME OF MEETING 2:00pm (NZT) PLACE OF MEETING Pullman Auckland, Regatta Room, Lower Lobby Level, Cnr Princes St & Waterloo Quadrant, Auckland City, New Zealand

Read More Read Less
Load More

— 16 September 2017

Sir Richard Faull on RNZ National

On Saturday Morning on RNZ National, LCT Scientific Advisor Sir Richard Faull and businessman Bernie Crosby talk to Kim Hill about the work of the University of Auckland Centre for Brain Research and finding a cure for Parkinson's disease.

Read More Read Less

— 13 June 2017

Pig brain cells implanted into brains of people with Parkinson’s

Would you have pig cells implanted in your brain? Some people with Parkinson’s disease have, in the hope it will stop their disease progressing. The approach is still in the early stages of testing, but initial results from four people look promising, with all showing some improvement 18 months after surgery. Living Cell Technologies, based in Auckland, New Zealand, has been developing a treatment that uses cells from the choroid plexus in pigs. This brain structure makes a cocktail of growth factors and signalling molecules known to help keep nerve cells healthy.

Read More Read Less
Load More
icon
— 7 November 2019

LCT Annual General Meeting. To be held at 2pm (NZT) Pullman Auckland, Regatta Room, Lower Lobby Level, Cnr Princes St & Waterloo Quadrant, Auckland City, New Zealand

Load More
Announcements

— 15 October 2019

LCT extends cash runway with receipt from Vertex

LCT has received Net AUD 1,100,158 from the acquisition of Semma Therapeutics, a private company in which LCT held shares, by Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Read More Read Less

— 4 October 2019

Notice of AGM and proxy form

NOTICE OF ANNUAL GENERAL MEETING DATE OF MEETING Thursday 7 November 2019 TIME OF MEETING 2:00pm (NZT) PLACE OF MEETING Pullman Auckland, Regatta Room, Lower Lobby Level, Cnr Princes St & Waterloo Quadrant, Auckland City, New Zealand

Read More Read Less
Load More
LCT in the News

— 16 September 2017

Sir Richard Faull on RNZ National

On Saturday Morning on RNZ National, LCT Scientific Advisor Sir Richard Faull and businessman Bernie Crosby talk to Kim Hill about the work of the University of Auckland Centre for Brain Research and finding a cure for Parkinson's disease.

Read More Read Less

— 13 June 2017

Pig brain cells implanted into brains of people with Parkinson’s

Would you have pig cells implanted in your brain? Some people with Parkinson’s disease have, in the hope it will stop their disease progressing. The approach is still in the early stages of testing, but initial results from four people look promising, with all showing some improvement 18 months after surgery. Living Cell Technologies, based in Auckland, New Zealand, has been developing a treatment that uses cells from the choroid plexus in pigs. This brain structure makes a cocktail of growth factors and signalling molecules known to help keep nerve cells healthy.

Read More Read Less
Load More
Events
icon
— 7 November 2019

LCT Annual General Meeting. To be held at 2pm (NZT) Pullman Auckland, Regatta Room, Lower Lobby Level, Cnr Princes St & Waterloo Quadrant, Auckland City, New Zealand

Load More
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.